Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders

Takahiro Watanabe, Yoshitaka Sato, H. M.Abdullah Al Masud, Masahiro Takayama, Hiroki Matsuda, Yuya Hara, Yusuke Yanagi, Masahiro Yoshida, Fumi Goshima, Takayuki Murata, Hiroshi Kimura

Research output: Contribution to journalArticle

Abstract

Epstein-Barr virus (EBV) is a well-established tumor virus that has been implicated in a wide range of immunodeficiency-associated lymphoproliferative disorders (LPDs). Although rituximab, a CD20 mAb, has proven effective against EBV-associated LPDs, prolonged use of this drug could lead to resistance due to the selective expansion of CD20 cells. We have previously shown that cyclin-dependent kinase (CDK) inhibitors are able to specifically suppress the expression of viral late genes, particularly those encoding structural proteins; however, the therapeutic effect of CDK inhibitors against EBV-associated LPDs is not clear. In this study, we examined whether CDK inhibitors confer a therapeutic effect against LPDs in vivo. Treatment with alsterpaullone, an inhibitor of the CDK2 complex, resulted in a survival benefit and suppressed tumor invasion in a mouse model of LPDs. Inhibition of CDK efficiently induced G1 cell cycle arrest and apoptosis in EBV-positive B cells. These results suggest that alsterpaullone suppresses cell cycle progression, resulting in the antitumor effect observed in vivo.

Original languageEnglish
Pages (from-to)279-287
Number of pages9
JournalCancer science
Volume111
Issue number1
DOIs
Publication statusPublished - 01-01-2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders'. Together they form a unique fingerprint.

  • Cite this

    Watanabe, T., Sato, Y., Masud, H. M. A. A., Takayama, M., Matsuda, H., Hara, Y., Yanagi, Y., Yoshida, M., Goshima, F., Murata, T., & Kimura, H. (2020). Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders. Cancer science, 111(1), 279-287. https://doi.org/10.1111/cas.14241